Skip to main content

A Study to Evaluate Lipid Profile in Treatment Naïve HIV Positive Patients

Indian Journal of Clinical Biochemistry volume 29, pages 45–50 (2014)Cite this article

Abstract

HIV infection is associated with lipid abnormalities in treatment naïve patients. CD4 count is used for monitoring the HIV infection. Primary objective was to evaluate and correlate lipid profile and CD4 counts in HIV infection. Secondary objective was to evaluate the feasibility of using Lipid profile to monitor the HIV infected treatment naïve patients instead of CD4 counts. 112 patients were selected based on a criteria from ART center in tertiary care center. CD4 counts were assessed and Lipid profile was evaluated enzymatically. A correlation study was done between the lipid profile and the CD4 count and clinical stages of infection. Cholesterol showed no significant correlation in any stage. HDL-C showed significant correlation (p < 0.05) with stage 2 and 4 disease. LDL-C showed no significant correlation in any stage. TGL showed significant correlation (p < 0.05) at stage 4 disease. Hence, HDL-C and TGL can be used as indicators of lipid status and for infection progression in treatment naive HIV patients, while Cholesterol and LDL-C has no role to play.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60.

    PubMed  Article  Google Scholar 

  2. Kingsley L, Smit E, Riddler S, Li R, Chmiel J, Palella F, et al. Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS) [Abstract 538]. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: 2001. Feb 4–8.

  3. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. Use of Human Immunodeficiency Virus-1 Protease Inhibitors is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction. Circulation. 2001;104:257–64.

    CAS  PubMed  Article  Google Scholar 

  4. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(7):F51–8.

    CAS  PubMed  Article  Google Scholar 

  5. Périard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. For the Swiss HIV Cohort Study. Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors. Circulation. 1999;100:700–5.

    PubMed  Article  Google Scholar 

  6. Bonnet F, Savès M, Cécile D, Peuchant E, Geneviève C, Beylot J, et al. Increase of Atherogenic Plasma Profile in HIV-Infected Patients Treated With Protease Inhibitor-Containing Regimens. J Acquir Immune Defic Syndr. 2000;25:199–200.

    CAS  PubMed  Article  Google Scholar 

  7. Berthold HK, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Schliefer K, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med. 1999;246(6):567–75.

    CAS  PubMed  Article  Google Scholar 

  8. Mary-Krause M, Cotte L, Partisani M, Simon A, Costagliola D. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men [Abstract 657]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago).Washington, DC: Foundation for Retrovirology and Human Health; 2001.

  9. Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS. 2000;14(16):123–8.

    Article  Google Scholar 

  10. Friis-Moller N, Weber R, D’Arminio Monforte A, El-Sadr W, Reiss P, Dabis F, et al. Exposure to HAART is associated with an increased risk of myocardial infarction: the DAD Study [Abstract 130]. 10th Conference on Retroviruses and Opportunistic Infections, Boston 2003. Feb 10–14.

  11. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, et al. Severe premature coronary artery disease associated with protease inhibitors [letter]. Lancet. 1998;351:1328.

    CAS  PubMed  Article  Google Scholar 

  12. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348(8):702–10.

    CAS  PubMed  Article  Google Scholar 

  13. Grunfeld C, Feingold KR. Metabolic Disturbances and Wasting in the Acquired Immunodeficiency Syndrome. N Engl J Med. 1992;327:329–37.

    CAS  PubMed  Article  Google Scholar 

  14. Grunfeld C, Pang M, Doerrier W, Shigenaga JK, Jensen P, Feingold KR. Lipids, Lipoproteins, Triglyceride clearance and cytokines in Human Immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74(5):1045–52.

    CAS  PubMed  Google Scholar 

  15. Tang AM, Bhatnagar T, Ramachnadran R, Dong K, Skimer S, Kumar MS, et al. Malnutrition in apopulation of HIV-positive and HIV-negative drug users living in Chennai, South India. Drug Alcohol Depend. 2011;118(1):73–7.

    PubMed Central  PubMed  Article  Google Scholar 

  16. Grunfeld C, Kotler DP, Shingenaga JK, Doerrler W, Tiernay A, Wang J, et al. Circulating Interferon-alpha levels and Hypertriglyceridaemia in the Acquired immunodeficiency Syndrome. Am J Med. 1991;90:154–62.

    CAS  PubMed  Google Scholar 

  17. Constans J, Pellegrin JL, Peuchant E, Dumon MF, Pellegrin I, Sergeant C, et al. Plasma lipids in HIV-infected patients :a prospective study in 95 patients. Eur J Clin Invest. 1994;24(6):416–20.

    CAS  PubMed  Article  Google Scholar 

  18. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr. 1985;42(6):1255–65.

    CAS  PubMed  Google Scholar 

  19. Khiangte L, Vidyabati RK, Singh MK, Devi SB, Singh TR, Singh WG. A Study of Serum Lipid Profile in Human Immunodeficiency Virus (HIV) Infected Patients. J Ind Acad Clin Med. 2007;8:307–11.

    Google Scholar 

  20. Kipp HA. Variation in the cholesterol content of serum in pneumonia. J Biol Chem. 1920;44:215–37.

    CAS  Google Scholar 

  21. Alvarez C, Ramos A. Lipids, lipoproteins and apolipoproteins in serum during infection. Clin Chem. 1986;32:142–5.

    CAS  PubMed  Google Scholar 

  22. Nilsson EI, Nilsson EP. Changes in the plasma lipoproteins in acute malaria. J Intern Med. 1990;227:151–5.

    Article  Google Scholar 

  23. Baillee EE, Orr CW. Lowered high density lipoprotein cholesterol in viral illness. Clin Chem. 1979;25:817–8.

    Google Scholar 

  24. Friedlans ML, Herbert PN. Lipoprotein abnormalities is associated with a viral syndrome. JAMA. 1982;248(1):82.

    Article  Google Scholar 

  25. Grunfeld C, Feingold KR. Regulation of lipid metabolism by cytokines during host defense. Nutrition. 1996;12(1):S24–6.

    CAS  PubMed  Article  Google Scholar 

  26. Jahoor F, Gazzard B, Phillips G, Sharpstone D, Delrosario M, Frazer ME, et al. The acute phase protein response to human immunodeficiency virus infection in human subjects. Am. J. Physiol. 1999;27:6. Pt 1:E1092–E1098.

    Google Scholar 

  27. Feingold KR, Memon RA, Moser AH, Shigenaga JK, Grunfeld C. Endotoxin and interleukin-1 decrease hepatic lipase mRNA levels. Atherosclerosis. 1999;142(2):379–87.

    CAS  PubMed  Article  Google Scholar 

  28. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes. 1992;41:97–101.

    CAS  PubMed  Article  Google Scholar 

  29. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acq Immune Defic Syndr. 1994;7:1149–56.

    CAS  Google Scholar 

  30. Treitinger A, Spade C. Lipid and acute phase protein alterations in HIV -1 infected patients in the early stages of infection; correlation with cd4 lymphocytes. Brazilian J Infect dis. 2001;5(4):192–9.

    CAS  Google Scholar 

  31. Waigmann HR, Schröder B, Biesert L, Bauremeister D, Briesen HV, Suhartono H, et al. Markers for HIV-disease progression in untreated patients and patients receiving AZT: evaluation of viral activity, AZT resistance, serum cholesterol, β2-microglobulin, CD4 + cell counts, and HIV antigen. Infection. 1991;19:77–82.

    Article  Google Scholar 

  32. El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005;6:114–21.

    CAS  PubMed  Article  Google Scholar 

  33. Miranda FC, Pulido F, Carrillo JL, Larumbe S. Gómez Izquierdo T, Ortuño B, et al. Lipoprotein alterations in patients with HIV infection: relation with cellular and humoral immune markers. Clin Chim Acta. 1998;274(1):63–70.

    Article  Google Scholar 

  34. Kritz H, Efthimiou Y, Stamatopoulos J, Najemnik C, Sinzinger H. Association of lipoprotein(a), prostaglandin I(2)–synthesis stimulating plasma factor, biological half-life of prostaglandin I(2)and high-density lipoproteins in HIV-1 infection of different stages. Prostaglandins Leukot Essent Fatty Acids. 2000;63(5):309–14.

    CAS  PubMed  Article  Google Scholar 

  35. Owens BJ, Anantharamaiah GM, Kahlon JB, Srinivas RV, Compans RW, Segrest JP. Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. J Clin Invest. 1990;86(4):1142–50.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  36. Mikhail NE. Lipid abnormalities in patients infected with human immunodeficiency virus. Endocr Pract Official J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2008;14(4):492–500.

    Google Scholar 

  37. Hardardottir I, Grunfeld C, Feingold KR. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol. 1994;5:207–15.

    CAS  PubMed  Article  Google Scholar 

  38. Grunfeld C, Feingold KR. The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS. J Nutr. 1992;122:749–53.

    CAS  PubMed  Google Scholar 

  39. Gouni I, Oka K, Etienne J, Chan L. Endotoxin-induced hypertriglyceridemia is mediated by suppression of lipoprotein lipase at a post-transcriptional level. J Lipid Res. 1993;34(1):139–46.

    CAS  PubMed  Google Scholar 

  40. Edgington Thomas S, Curtiss Linda K. Plasma Lipoproteins with bioregulatory Properties including the Capacity to Regulate Lymphocyte Function and the Immune Response. Cancer Res. 1981;41:3786–8.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to place on record our gratitude to Research Society for providing the financial support towards conducting this study.

Author information

Affiliations

  1. Division of Clinical Biochemistry, Department of Biochemistry, St. John’s Medical College, Bangalore, 560034, Karnataka, India

    Anitha Devanath

  2. St. John’s Medical College, Bangalore, 560034, Karnataka, India

    Somdattaa Ray & Ravi Kumar

  3. St. John’s Medical College and Hospital, Bangalore, Karnataka, India

    B. S. Prarthana

Authors
  1. Anitha Devanath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Somdattaa Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ravi Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. S. Prarthana
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anitha Devanath.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Devanath, A., Ray, S., Kumar, R. et al. A Study to Evaluate Lipid Profile in Treatment Naïve HIV Positive Patients. Ind J Clin Biochem 29, 45–50 (2014). https://doi.org/10.1007/s12291-012-0295-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-012-0295-7

Keywords

  • Lipid profile
  • Treatment naïve HIV infected patients
  • NACO based clinical staging